Background & Aims: Multiple lymphomatous polyposis (MLP) is an uncommon type of gastrointestinal lymphoma. The aim of this study was to analyze the clinicopathologic features and outcome of a large series of patients.

Methods: From 1984 to 1995, 31 patients were enrolled prospectively. Exhaustive staging and immunohistochemical analysis were performed. The first 10 patients were treated with cyclophosphamide-vincristine-prednisolone (COP) and the subsequent 21 with doxorubicin-teniposide-cyclophosphamide-prednisolone (AVmCP). Eleven patients were treated with high-dose radiochemotherapy and stem cell autotransplantation because of partial response or relapse.

Results: Advanced age and multiple polyps involving several gastrointestinal segments characterized initial clinical presentation. The typical tumor cell phenotype (pan-B+, CD5+, and CD10-) along with Bcl-1 rearrangement indicated that MLP is the gastrointestinal counterpart of mantle cell lymphoma. After COP treatment, only 3 patients achieved partial remissions, whereas 80% of patients after AVmCP treatment achieved complete or good partial remission. High-dose radiochemotherapy changed partial into complete remission in 80% of cases. None of the initial 10 patients survived for 3 years, but the expected 5-year survival rate was 59% in patients receiving the anthracycline-containing regimen (P < 0.0001).

Conclusions: MLP is a distinct entity among gastrointestinal lymphomas. An anthracycline-containing multidrug regimen and high-dose radiochemotherapy supported by autotransplantation seem to improve its poor prognosis.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0016-5085(97)70212-9DOI Listing

Publication Analysis

Top Keywords

high-dose radiochemotherapy
12
multiple lymphomatous
8
lymphomatous polyposis
8
patients treated
8
patients
7
gastrointestinal
5
polyposis gastrointestinal
4
gastrointestinal tract
4
tract prospective
4
prospective clinicopathologic
4

Similar Publications

Purpose: To compare the clinical outcomes of two different schedules of modern image-guided adaptive brachytherapy (IGABT) in patients underwent chemoradiotherapy (CCRT) and high-dose rate (HDR) brachytherapy (BT) for locally advanced cervical cancer treated (LACC) METHODS AND MATERIALS: Data from medical records of all consecutive patients with histologically proven cervical cancer (FIGO 2018 stage IB-IVA) treated by HDR-BT after CCRT at our institution between 2016 and 2021 were reviewed.

Results: Two hundred and 8 patients with LACC FIGO 2018 stages (IB 20.7%; II 26.

View Article and Find Full Text PDF

Cisplatin is a nephrotoxic agent able to damage renal function both in acute and chronic phases. Radiotherapy concomitant with cisplatin 100 mg/m given once every 3 weeks is the curative standard of care for locally advanced head and neck cancer. A prospective evaluation of a wide range of biochemical and anthropometrical parameters, handgrip strength, risk of malnutrition, visual analogue scale of appetite, and body composition was performed before, during, and after concomitant chemoradiotherapy in 60 consecutive patients affected by locally advanced head and neck cancer.

View Article and Find Full Text PDF
Article Synopsis
  • A study explored how dose escalation in radiotherapy could benefit specific subgroups of esophageal cancer (EC) patients undergoing concurrent chemoradiotherapy (CCRT).
  • Researchers analyzed data from 187 EC patients treated between 2008 and 2022, comparing high-dose (HD) and low-dose (LD) radiotherapy effectiveness using a predictive model based on clinical and radiomic features.
  • The findings revealed a distinct subgroup of patients that significantly benefitted from HD-RT, showcasing improved overall survival rates, thus suggesting the model could help clinicians in determining appropriate treatment doses.
View Article and Find Full Text PDF

Background: High-risk medulloblastoma (HRMB) is rare in adults. The 5-year overall survival rate is less than 60%. We present here a retrospective analysis of adults treated with an intensive pediatric chemo-radiotherapy regimen PNET HR + 5: NCT00936156.

View Article and Find Full Text PDF

Case report: The role and value of radiotherapy in treatment of inflammatory myofibroblastic tumor.

Front Oncol

November 2024

Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China.

Background: Inflammatory myofibroblastic tumors (IMTs) are rare soft-tissue neoplasms. Accordingly, there is no standardized therapy for unresectable or advanced IMT. Chemotherapy, radiotherapy, and targeted molecular therapy play an important role in unresectable or advanced IMT.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!